 Carlo Marchetti
Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NLR Family, Pyrin Domain-Containing 3 Protein | 16 | 2024 | 149 | 4.520 |
Why?
| | Inflammasomes | 15 | 2024 | 126 | 3.710 |
Why?
| | Anti-Inflammatory Agents | 5 | 2020 | 481 | 1.880 |
Why?
| | Myocardial Reperfusion Injury | 7 | 2017 | 129 | 1.470 |
Why?
| | Carrier Proteins | 7 | 2016 | 740 | 1.320 |
Why?
| | Nitriles | 4 | 2021 | 169 | 1.300 |
Why?
| | Interleukin-1beta | 8 | 2024 | 368 | 0.920 |
Why?
| | Inflammation | 8 | 2024 | 2741 | 0.920 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2021 | 64 | 0.840 |
Why?
| | Interleukin-1 | 6 | 2024 | 954 | 0.800 |
Why?
| | Myocardial Ischemia | 4 | 2016 | 259 | 0.730 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 107 | 0.720 |
Why?
| | Macrophages | 3 | 2018 | 1486 | 0.670 |
Why?
| | Arthritis, Reactive | 1 | 2018 | 8 | 0.600 |
Why?
| | Arthritis, Gouty | 1 | 2018 | 14 | 0.590 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 417 | 0.570 |
Why?
| | Arthritis, Experimental | 1 | 2018 | 135 | 0.530 |
Why?
| | Inflammation Mediators | 1 | 2019 | 503 | 0.520 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2022 | 326 | 0.480 |
Why?
| | Dimethyl Sulfoxide | 1 | 2015 | 41 | 0.470 |
Why?
| | Animals | 31 | 2024 | 35334 | 0.470 |
Why?
| | Myocardial Infarction | 6 | 2017 | 1018 | 0.430 |
Why?
| | Benzamides | 1 | 2014 | 203 | 0.410 |
Why?
| | Cardiovascular Agents | 4 | 2017 | 157 | 0.380 |
Why?
| | Mice | 21 | 2023 | 16973 | 0.380 |
Why?
| | Caspase 1 | 6 | 2018 | 142 | 0.360 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 339 | 0.350 |
Why?
| | Sulfonamides | 1 | 2014 | 497 | 0.340 |
Why?
| | Interleukin-18 | 3 | 2018 | 237 | 0.330 |
Why?
| | Neoplasms | 1 | 2023 | 2450 | 0.310 |
Why?
| | Sepsis | 1 | 2015 | 576 | 0.300 |
Why?
| | Signal Transduction | 8 | 2024 | 4916 | 0.290 |
Why?
| | Cytokines | 4 | 2024 | 2018 | 0.290 |
Why?
| | Ventricular Function, Left | 6 | 2017 | 529 | 0.280 |
Why?
| | Peritonitis | 2 | 2019 | 81 | 0.260 |
Why?
| | Myocardial Reperfusion | 2 | 2017 | 50 | 0.260 |
Why?
| | alpha 1-Antitrypsin | 2 | 2017 | 107 | 0.240 |
Why?
| | Mice, Inbred C57BL | 8 | 2022 | 5468 | 0.240 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2015 | 385 | 0.230 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2024 | 171 | 0.220 |
Why?
| | Myocardium | 3 | 2017 | 981 | 0.210 |
Why?
| | Receptors, Interleukin-1 Type I | 2 | 2020 | 23 | 0.200 |
Why?
| | Mice, Knockout | 5 | 2021 | 2887 | 0.190 |
Why?
| | Wnt Signaling Pathway | 1 | 2023 | 169 | 0.190 |
Why?
| | Interleukin-6 | 3 | 2021 | 724 | 0.180 |
Why?
| | Cardiomyopathies | 2 | 2015 | 339 | 0.180 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2019 | 253 | 0.180 |
Why?
| | Reactive Oxygen Species | 1 | 2023 | 591 | 0.170 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 391 | 0.160 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 194 | 0.160 |
Why?
| | Colitis | 1 | 2022 | 245 | 0.160 |
Why?
| | Lipopolysaccharides | 3 | 2018 | 872 | 0.160 |
Why?
| | Immunity, Innate | 2 | 2016 | 804 | 0.160 |
Why?
| | Drug Design | 1 | 2019 | 157 | 0.150 |
Why?
| | Mice, Inbred ICR | 2 | 2016 | 111 | 0.150 |
Why?
| | Uric Acid | 1 | 2019 | 161 | 0.150 |
Why?
| | Intestinal Mucosa | 1 | 2023 | 593 | 0.150 |
Why?
| | Stroke Volume | 3 | 2016 | 593 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 372 | 0.140 |
Why?
| | Male | 16 | 2020 | 63586 | 0.140 |
Why?
| | Disease Models, Animal | 9 | 2020 | 4073 | 0.140 |
Why?
| | Relaxin | 1 | 2017 | 18 | 0.140 |
Why?
| | Cells, Cultured | 4 | 2018 | 4087 | 0.140 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2017 | 201 | 0.130 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2016 | 39 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 347 | 0.120 |
Why?
| | Humans | 15 | 2024 | 129527 | 0.120 |
Why?
| | Dietary Sucrose | 1 | 2015 | 48 | 0.120 |
Why?
| | Radiation Injuries, Experimental | 1 | 2015 | 22 | 0.120 |
Why?
| | Myocarditis | 1 | 2016 | 98 | 0.120 |
Why?
| | Angiotensin II | 1 | 2015 | 95 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 855 | 0.120 |
Why?
| | Alzheimer Disease | 1 | 2020 | 516 | 0.120 |
Why?
| | Melanoma | 1 | 2021 | 728 | 0.110 |
Why?
| | Ventricular Remodeling | 2 | 2014 | 256 | 0.110 |
Why?
| | Hydrogen Sulfide | 1 | 2014 | 42 | 0.110 |
Why?
| | Diet, High-Fat | 1 | 2015 | 239 | 0.110 |
Why?
| | Doxorubicin | 1 | 2015 | 328 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2014 | 282 | 0.100 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2014 | 208 | 0.100 |
Why?
| | Heart Failure | 2 | 2015 | 2143 | 0.090 |
Why?
| | Repressor Proteins | 1 | 2014 | 404 | 0.090 |
Why?
| | Heart Diseases | 1 | 2014 | 349 | 0.090 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1366 | 0.080 |
Why?
| | Cell Line | 1 | 2014 | 2774 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 1997 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2023 | 373 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 677 | 0.070 |
Why?
| | Tissue Survival | 2 | 2017 | 16 | 0.070 |
Why?
| | Time Factors | 4 | 2017 | 6530 | 0.060 |
Why?
| | Systole | 2 | 2015 | 190 | 0.060 |
Why?
| | Blood Glucose | 1 | 2014 | 2071 | 0.060 |
Why?
| | Caspase 3 | 2 | 2014 | 244 | 0.050 |
Why?
| | Myocardial Contraction | 2 | 2014 | 334 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2020 | 2135 | 0.050 |
Why?
| | Organoids | 1 | 2023 | 104 | 0.050 |
Why?
| | Dextran Sulfate | 1 | 2022 | 79 | 0.050 |
Why?
| | Interleukins | 1 | 2023 | 241 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2022 | 2697 | 0.050 |
Why?
| | Models, Immunological | 1 | 2021 | 96 | 0.040 |
Why?
| | Behavior Observation Techniques | 1 | 2020 | 9 | 0.040 |
Why?
| | Presenilin-1 | 1 | 2020 | 31 | 0.040 |
Why?
| | Spatial Memory | 1 | 2020 | 23 | 0.040 |
Why?
| | Apoptosis | 3 | 2014 | 2488 | 0.040 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2020 | 61 | 0.040 |
Why?
| | Gene Deletion | 1 | 2022 | 379 | 0.040 |
Why?
| | Tumor Burden | 1 | 2021 | 287 | 0.040 |
Why?
| | Homeostasis | 1 | 2023 | 605 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 574 | 0.040 |
Why?
| | Myocytes, Cardiac | 2 | 2014 | 492 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2021 | 356 | 0.040 |
Why?
| | Microglia | 1 | 2020 | 234 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 783 | 0.040 |
Why?
| | Leukocytes | 1 | 2019 | 304 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2020 | 278 | 0.040 |
Why?
| | Pyrazoles | 1 | 2021 | 403 | 0.040 |
Why?
| | Pyrimidines | 1 | 2021 | 458 | 0.040 |
Why?
| | Cytoprotection | 1 | 2017 | 56 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2020 | 439 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2020 | 495 | 0.030 |
Why?
| | Nitrites | 1 | 2017 | 83 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 738 | 0.030 |
Why?
| | Troponin I | 1 | 2017 | 75 | 0.030 |
Why?
| | Leukocyte Elastase | 1 | 2016 | 77 | 0.030 |
Why?
| | Infusions, Subcutaneous | 1 | 2015 | 21 | 0.030 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2017 | 206 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 763 | 0.030 |
Why?
| | Caspase 7 | 1 | 2014 | 22 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2015 | 133 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 86 | 0.030 |
Why?
| | Candida | 1 | 2014 | 37 | 0.030 |
Why?
| | Interleukin-1alpha | 1 | 2014 | 56 | 0.030 |
Why?
| | Isoproterenol | 1 | 2014 | 116 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 3181 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1311 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 328 | 0.030 |
Why?
| | Sulfides | 1 | 2014 | 95 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2014 | 127 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2016 | 650 | 0.030 |
Why?
| | Histone Deacetylases | 1 | 2014 | 211 | 0.030 |
Why?
| | Fibrosis | 1 | 2015 | 526 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2012 | 127 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2014 | 546 | 0.020 |
Why?
| | Antibodies | 1 | 2014 | 398 | 0.020 |
Why?
| | Monocytes | 1 | 2014 | 554 | 0.020 |
Why?
| | Echocardiography | 1 | 2014 | 635 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 832 | 0.020 |
Why?
| | Hemodynamics | 1 | 2015 | 1094 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1203 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5470 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3968 | 0.020 |
Why?
| | Blood Pressure | 1 | 2015 | 1735 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2734 | 0.020 |
Why?
| | Female | 3 | 2016 | 68650 | 0.010 |
Why?
|
|
Marchetti's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|